Investment group RSJ's fund Gradus has appreciated its investments in the biopharmaceutical company BioXcel Therapeutics. This was thanks to the results in the development of treatment for acute psychiatric phenomena such as agitation accompanying schizophrenia, bipolar disorder, delirium and addiction treatment. BioXcel Therapeutics published the results of the third phase of clinical trials of the drug BXCL501, and its Nasdaq-listed shares appreciated up to tenfold. According to fund Gradus General Manager Michal Votruba, the drug could help up to 150 million patients.
Prepared by the team of foreign office CzechTrade Chicago